Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
57
MKGAF Quote, Financials, Valuation and Earnings
Last price:
$147.47
Seasonality move
:
-3.71%
Day range:
$139.23 - $148.00
52-week range:
$118.05 - $159.75
Dividend yield:
1.75%
P/E ratio:
19.06x
P/S ratio:
2.66x
P/B ratio:
1.84x
Volume:
531
Avg. volume:
502
1-year change:
1.3%
Market cap:
$62.5B
Revenue:
$22.9B
EPS (TTM):
$7.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MKGAF
Merck KGaA
|
$6B | -- | 6.17% | -- | -- |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MKGAF
Merck KGaA
|
$143.75 | -- | $62.5B | 19.06x | $2.51 | 1.75% | 2.66x |
|
BNTX
BioNTech SE
|
$95.03 | $138.33 | $22.9B | 191.55x | $0.00 | 0% | 6.46x |
|
CVAC
CureVac NV
|
$4.31 | $5.31 | $970.5M | 6.03x | $0.00 | 0% | 11.97x |
|
IFRX
InflaRx NV
|
$1.14 | $11.24 | $77.2M | -- | $0.00 | 0% | 352.24x |
|
IMTX
Immatics NV
|
$10.37 | $18.75 | $1.3B | 42.21x | $0.00 | 0% | 13.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MKGAF
Merck KGaA
|
29.49% | 0.006 | 25.01% | 0.76x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MKGAF
Merck KGaA
|
$3.8B | $1.4B | 7.45% | 10.11% | 22.9% | $604.6M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Merck KGaA vs. Competitors
-
Which has Higher Returns MKGAF or BNTX?
BioNTech SE has a net margin of 16.89% compared to Merck KGaA's net margin of -1.89%. Merck KGaA's return on equity of 10.11% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital MKGAFMerck KGaA60.42% $2.42 $48.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About MKGAF or BNTX?
Merck KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 45.57%. Given that BioNTech SE has higher upside potential than Merck KGaA, analysts believe BioNTech SE is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKGAFMerck KGaA0 0 0 BNTXBioNTech SE14 5 0 -
Is MKGAF or BNTX More Risky?
Merck KGaA has a beta of 0.937, which suggesting that the stock is 6.271% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock MKGAF or BNTX?
Merck KGaA has a quarterly dividend of $2.51 per share corresponding to a yield of 1.75%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 34.44% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKGAF or BNTX?
Merck KGaA quarterly revenues are $6.2B, which are larger than BioNTech SE quarterly revenues of $1.8B. Merck KGaA's net income of $1B is higher than BioNTech SE's net income of -$33.5M. Notably, Merck KGaA's price-to-earnings ratio is 19.06x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.66x versus 6.46x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKGAFMerck KGaA2.66x 19.06x $6.2B $1B BNTXBioNTech SE6.46x 191.55x $1.8B -$33.5M
-
Which has Higher Returns MKGAF or CVAC?
CureVac NV has a net margin of 16.89% compared to Merck KGaA's net margin of -5832.47%. Merck KGaA's return on equity of 10.11% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital MKGAFMerck KGaA60.42% $2.42 $48.3B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About MKGAF or CVAC?
Merck KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 23.51%. Given that CureVac NV has higher upside potential than Merck KGaA, analysts believe CureVac NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKGAFMerck KGaA0 0 0 CVACCureVac NV1 3 0 -
Is MKGAF or CVAC More Risky?
Merck KGaA has a beta of 0.937, which suggesting that the stock is 6.271% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock MKGAF or CVAC?
Merck KGaA has a quarterly dividend of $2.51 per share corresponding to a yield of 1.75%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 34.44% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKGAF or CVAC?
Merck KGaA quarterly revenues are $6.2B, which are larger than CureVac NV quarterly revenues of $63.3M. Merck KGaA's net income of $1B is higher than CureVac NV's net income of $319.3M. Notably, Merck KGaA's price-to-earnings ratio is 19.06x while CureVac NV's PE ratio is 6.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.66x versus 11.97x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKGAFMerck KGaA2.66x 19.06x $6.2B $1B CVACCureVac NV11.97x 6.03x $63.3M $319.3M
-
Which has Higher Returns MKGAF or IFRX?
InflaRx NV has a net margin of 16.89% compared to Merck KGaA's net margin of -51538.49%. Merck KGaA's return on equity of 10.11% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital MKGAFMerck KGaA60.42% $2.42 $48.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About MKGAF or IFRX?
Merck KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 886.3%. Given that InflaRx NV has higher upside potential than Merck KGaA, analysts believe InflaRx NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKGAFMerck KGaA0 0 0 IFRXInflaRx NV5 2 0 -
Is MKGAF or IFRX More Risky?
Merck KGaA has a beta of 0.937, which suggesting that the stock is 6.271% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock MKGAF or IFRX?
Merck KGaA has a quarterly dividend of $2.51 per share corresponding to a yield of 1.75%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 34.44% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKGAF or IFRX?
Merck KGaA quarterly revenues are $6.2B, which are larger than InflaRx NV quarterly revenues of $27.8K. Merck KGaA's net income of $1B is higher than InflaRx NV's net income of -$14.3M. Notably, Merck KGaA's price-to-earnings ratio is 19.06x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.66x versus 352.24x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKGAFMerck KGaA2.66x 19.06x $6.2B $1B IFRXInflaRx NV352.24x -- $27.8K -$14.3M
-
Which has Higher Returns MKGAF or IMTX?
Immatics NV has a net margin of 16.89% compared to Merck KGaA's net margin of -974.45%. Merck KGaA's return on equity of 10.11% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital MKGAFMerck KGaA60.42% $2.42 $48.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About MKGAF or IMTX?
Merck KGaA has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 80.81%. Given that Immatics NV has higher upside potential than Merck KGaA, analysts believe Immatics NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKGAFMerck KGaA0 0 0 IMTXImmatics NV9 0 0 -
Is MKGAF or IMTX More Risky?
Merck KGaA has a beta of 0.937, which suggesting that the stock is 6.271% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock MKGAF or IMTX?
Merck KGaA has a quarterly dividend of $2.51 per share corresponding to a yield of 1.75%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 34.44% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKGAF or IMTX?
Merck KGaA quarterly revenues are $6.2B, which are larger than Immatics NV quarterly revenues of $6.1M. Merck KGaA's net income of $1B is higher than Immatics NV's net income of -$59.1M. Notably, Merck KGaA's price-to-earnings ratio is 19.06x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.66x versus 13.85x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKGAFMerck KGaA2.66x 19.06x $6.2B $1B IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
